Briacell Financial Statements From 2010 to 2024

BCTX Stock  USD 0.62  0.03  4.62%   
Briacell Therapeutics financial statements provide useful quarterly and yearly information to potential Briacell Therapeutics Corp investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Briacell Therapeutics financial statements helps investors assess Briacell Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Briacell Therapeutics' valuation are summarized below:
Market Capitalization
28.5 M
Earnings Share
(0.89)
We have found one hundred twenty available fundamental signals for Briacell Therapeutics Corp, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Briacell Therapeutics Corp prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 97.1 M in 2024. Enterprise Value is likely to rise to about 77 M in 2024
Check Briacell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Briacell Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 86.7 K, Interest Expense of 0.0 or Other Operating Expenses of 34.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Days Sales Outstanding of 0.0 or Invested Capital of 622.1 K. Briacell financial statements analysis is a perfect complement when working with Briacell Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Briacell Therapeutics Correlation against competitors.

Briacell Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets10.3 M5.9 M11.6 M
Slightly volatile
Total Current Liabilities7.8 M7.5 M1.9 M
Slightly volatile
Accounts Payable7.5 M7.2 M1.3 M
Slightly volatile
Cash819 K862.1 K8.5 M
Slightly volatile
Non Current Assets Total1.2 M2.2 M1.4 M
Slightly volatile
Cash And Short Term Investments819 K862.1 K8.7 M
Slightly volatile
Common Stock Shares Outstanding17.3 M16.5 M4.8 M
Slightly volatile
Liabilities And Stockholders Equity10.3 M5.9 M11.6 M
Slightly volatile
Non Current Liabilities TotalM1.1 M4.6 M
Slightly volatile
Other Stockholder Equity8.1 M11 M8.5 M
Pretty Stable
Total Liabilities4.8 M8.6 M5.8 M
Slightly volatile
Total Current Assets3.5 M3.7 M9.8 M
Slightly volatile
Net Receivables1.4 M1.4 M248.1 K
Slightly volatile
Other Current Liabilities275.9 K290.4 K643.3 K
Pretty Stable
Other Current Assets721.5 K1.4 M747.2 K
Slightly volatile
Intangible Assets182.9 K199.8 K123 K
Slightly volatile
Long Term Investments439.4 K418.5 K57.2 K
Slightly volatile
Common Stock41 M72.2 M25.3 M
Slightly volatile
Short and Long Term Debt Total22.2 K23.4 K641.3 K
Slightly volatile
Common Stock Total Equity79.2 M75.4 M30.8 M
Slightly volatile
Short and Long Term Debt262.4 K276.2 K922.9 K
Slightly volatile
Capital Stock45.8 M72.2 M26.2 M
Slightly volatile
Short Term Debt195.6 K205.9 K705.5 K
Slightly volatile
Non Current Liabilities Other37.8 M36 M11.2 M
Slightly volatile
Other Liabilities37.8 M36 M9.2 M
Slightly volatile
Long Term Debt22.2 K23.4 K112.2 K
Slightly volatile
Capital Surpluse4.2 M4.7 M5.1 M
Slightly volatile

Briacell Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Research Development28.1 M26.8 M6.1 M
Slightly volatile
Interest Income186.2 K288 K105.3 K
Slightly volatile
Reconciled Depreciation88.1 K83.9 K18.3 K
Slightly volatile
Cost Of Revenue86.7 K82.6 K23.9 K
Slightly volatile

Briacell Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow819 K862.1 K8.6 M
Slightly volatile
Stock Based Compensation1.9 M1.8 M890.5 K
Slightly volatile
Depreciation88.1 K83.9 K17.6 K
Slightly volatile
Issuance Of Capital Stock4.2 M4.4 M7.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Invested Capital622.1 K673.5 K819.1 K
Slightly volatile
Average Payables749.9 K714.2 K212 K
Slightly volatile
Capex To Depreciation5.956.26210
Slightly volatile
Cash Per Share1.491.569.6309
Slightly volatile
Days Payables Outstanding18.9 K18 K4.7 K
Slightly volatile
Net Current Asset Value357.4 K402 K437.8 K
Slightly volatile
Income Quality5.144.89222.3798
Slightly volatile
Tangible Asset Value628.6 K675.2 K828.4 K
Slightly volatile
Intangibles To Total Assets0.03230.0340.0883
Pretty Stable
Current Ratio0.470.489715.3402
Pretty Stable
Graham Number2.913.0652.1207
Slightly volatile
Capex Per Share0.00760.0085.2785
Slightly volatile
Average Receivables350.5 K333.8 K84.2 K
Slightly volatile
Interest Debt Per Share1.0E-41.0E-40.3385
Pretty Stable
Debt To Assets5.0E-45.0E-40.342
Slightly volatile
Payables Turnover0.01990.02110.8003
Slightly volatile
Days Of Payables Outstanding18.9 K18 K4.7 K
Slightly volatile
Long Term Debt To Capitalization4.0E-44.0E-44.0E-4
Slightly volatile
Quick Ratio0.470.489715.0644
Pretty Stable
Cash Ratio0.110.115512.675
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.111.171.6776
Slightly volatile
Debt Ratio5.0E-45.0E-40.342
Slightly volatile

Briacell Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap97.1 M92.5 M37.8 M
Slightly volatile
Working Capital357.4 K402 K437.8 K
Slightly volatile
Enterprise Value77 M73.4 M27 M
Slightly volatile

Briacell Fundamental Market Drivers

Cash And Short Term Investments862.1 K

Briacell Upcoming Events

20th of March 2024
Upcoming Quarterly Report
View
12th of June 2024
Next Financial Report
View
31st of January 2024
Next Fiscal Quarter End
View
23rd of October 2024
Next Fiscal Year End
View
31st of October 2023
Last Quarter Report
View
31st of July 2023
Last Financial Announcement
View

About Briacell Therapeutics Financial Statements

Briacell Therapeutics investors use historical fundamental indicators, such as Briacell Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Briacell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-3.8 K-3.6 K
Cost Of Revenue82.6 K86.7 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Briacell Stock Analysis

When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.